Compare NRP & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRP | GLPG |
|---|---|---|
| Founded | 2002 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | 452 |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2002 | N/A |
| Metric | NRP | GLPG |
|---|---|---|
| Price | $118.64 | $28.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $36.50 |
| AVG Volume (30 Days) | 14.7K | ★ 118.8K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $216,119,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.28 | ★ N/A |
| Revenue Growth | ★ 54.66 | N/A |
| 52 Week Low | $92.00 | $24.74 |
| 52 Week High | $128.60 | $37.78 |
| Indicator | NRP | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 41.03 |
| Support Level | $117.31 | $27.98 |
| Resistance Level | $123.40 | $34.04 |
| Average True Range (ATR) | 2.43 | 0.50 |
| MACD | 0.44 | 0.06 |
| Stochastic Oscillator | 100.00 | 48.72 |
Natural Resources Partners LP is a diversified natural resource company. It is engaged in the business of owning, managing and leasing a diversified portfolio of mineral properties in the United States, including interests in coal, trona and soda ash, crude oil and natural gas, construction aggregates, frac sand, and other natural resources. The company leases coal reserves to experience mine operators under long-term leases that grant the operator the right to mine its coal reserves in exchange for royalty payments. The company operates in two reportable segments namely: Mineral Rights and Soda Ash. the majority of the revenue is generated from the Mineral Rights segment. Geographically, the business activity of the group functions through the United States.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.